A high-throughput and highly automated genotoxicity screening assay

ALTEX. 2022;39(1):71-81. doi: 10.14573/altex.2102121. Epub 2021 Sep 28.

Abstract

The increasing number of compounds under development and chemicals in commerce that require safety assessments pose a serious challenge for regulatory agencies worldwide. In vitro screening using toxicogenomic biomarkers has been proposed as a first-tier screen in chemical assessment and has been endorsed internationally. We previously developed, evaluated, and validated an in vitro transcriptomic biomarker responsive to DNA damage-inducing (DDI) agents, namely TGx-DDI, for genotoxicity testing in human cells and demonstrated the feasibility of using TGx-DDI in a medium-throughput, cell-based genotoxicity testing system by implementing this biomarker with the Nanostring nCounter system. In this current study, we took advantage of Nanostring nCounter Plexset technology to develop a highly auto­mated, multiplexed, and high-throughput genotoxicity testing assay, designated the TGx-DDI Plexset assay, which can increase the screening efficiency eight-fold compared to standard nCounter technology while decreasing the hands-on time. We demonstrate the high-throughput capability of this assay by eliminating concentration determination and RNA extraction steps without compromising the specificity and sensitivity of TGx-DDI. Thus, we propose that this simple, highly automated, multiplexed high-throughput pipeline can be widely used in chemical screening and assessment.

Keywords: TGx-DDI; toxicogenomics; transcriptomic biomarker.

MeSH terms

  • Cell Line
  • DNA Damage
  • Gene Expression Profiling*
  • Genetic Markers
  • Humans
  • Mutagenicity Tests
  • Mutagens* / toxicity

Substances

  • Genetic Markers
  • Mutagens